Lowe’s Companies, Inc. (LOW): Are There Still Some Reasons For Optimism?

Lowe’s Companies, Inc.(LOW) shares saw a recent bid of $80.91 and 4.51M shares have exchanged hands in the recent trading session, yielding a -4.35% decline over the past week. The stock price decreased -0.52% or $0.42 versus $81.33 at the end of the prior session. This change led market cap to move at $69.73B, putting the price -6.19% below the 52-week high and 24.73% above the 52-week low. The company’s stock has a normal trading capacity of 5.40M shares while the relative volume is 0.84.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $89.54 while $100.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $10.46 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $69.00, which would be decrease of about -15% of its current value. The mean target of $89.00 should be compared with the price when the stock was languishing around $64.87 a share. And it remains to be seen which target price LOW can achieve without sacrificing much as the company is holding a 0.94% gain for the past twelve months.

By historical standards, Lowe’s Companies, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts to 25.40 times earnings, above the average P/E ratio of 22.71 times earnings. For now, Lowe’s Companies, Inc. is the toast of Wall Street as its ABR stands at 2.20 with 11 out of 30 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Lowe’s Companies, Inc. has a 0.97% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Lowe’s Companies, Inc. has far performed well this year, with the share price up 13.77% since January. Over the past 2 quarters, the stock is up 12.74%, compared with a gain of nearly 5.88% for 3 months and about -5.11% for the past 30 days.

Last time, the company failed Wall Street by reporting EPS of $1.03, smashing the consensus of $1.06 per share. Revenue for the quarter also did not kill consensus, coming in at $16.86B, compared to the consensus of 16.96B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.63. The company is expected to report EPS as high as $1.67 and as low as $1.59 per share. Similarly, full-year EPS forecasts have ranged between $3.53 and $4.00. The mean EPS estimate is $3.90. On the other side, sales forecasts for the current quarter are $19.54B. The stock is expected to report revenue as high as $19.88B and as low as $19.1B per share. Similarly, full-year sales forecasts have ranged between $63.81B and $65.04B. The mean revenue estimate is $64.6B.

Over the last 5 years, Lowe’s Companies, Inc. has averaged a 19.40% YoY EPS growth rate and a 5.30% revenue growth rate. Analysts are expecting EPS growth rates to be at 27.40% this quarter and EPS estimate for next year reflect a 14.39% growth rate.

Sell-side analysts also have something to say about this company. RBC Capital Mkts analysts stated on 02/03/2017 that they maintained their Outperform rating. Bernstein analysts stated on 06/02/2017 that they launched coverage on this stock with Underperform rating. Citigroup had a markedly different take on 19/12/2016, proposing that Lowe’s Companies, Inc. is now considered Neutral versus prior Buy rating. Telsey Advisory Group analysts stated on 08/12/2016 that they maintained their Market Perform rating.

Is Capital One Financial Corporation (COF) Running Out of Gas?

Capital One Financial Corporation(COF) shares saw a recent bid of $79.79 and 2.36M shares have exchanged hands in the recent trading session, yielding a -0.60% decline over the past week. The stock price increased 0.35% or $-0.28 versus $79.51 at the end of the prior session. This change led market cap to move at $38.40B, putting the price -17.67% below the 52-week high and 37.51% above the 52-week low. The company’s stock has a normal trading capacity of 2.91M shares while the relative volume is 0.81.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $96.37 while $111.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $14.63 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $80.00, which would be an increase of about 0% of its current value. The mean target of $98.00 should be compared with the price when the stock was languishing around $58.03 a share. And it remains to be seen which target price COF can achieve without sacrificing much as the company is holding a 9.96% gain for the past twelve months.

By historical standards, Capital One Financial Corporation remains a cheap stock. The company’s current price-earnings ratio amounts to 12.13 times earnings, below the average P/E ratio of 38.93 times earnings. For now, Capital One Financial Corporation is the toast of Wall Street as its ABR stands at 2.40 with 5 out of 26 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Capital One Financial Corporation has a 1.24% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Capital One Financial Corporation has far performed well this year, with the share price down -8.54% since January. Over the past 2 quarters, the stock is down -5.71%, compared with a fall of nearly -14.81% for 3 months and about -3.06% for the past 30 days.

Last time, the company failed Wall Street by reporting EPS of $1.54, smashing the consensus of $1.92 per share. Revenue for the quarter also did not kill consensus, coming in at $6.54B, compared to the consensus of 6.66B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.93. The company is expected to report EPS as high as $2.05 and as low as $1.75 per share. Similarly, full-year EPS forecasts have ranged between $7.26 and $7.70. The mean EPS estimate is $7.49. On the other side, sales forecasts for the current quarter are $6.68B. The stock is expected to report revenue as high as $6.76B and as low as $6.59B per share. Similarly, full-year sales forecasts have ranged between $26.85B and $27.31B. The mean revenue estimate is $27.09B.

Over the last 5 years, Capital One Financial Corporation has averaged a -0.30% YoY EPS growth rate and a 8.80% revenue growth rate. Analysts are expecting EPS growth rates to be at -1.00% this quarter and EPS estimate for next year reflect a 15.05% growth rate.

Sell-side analysts also have something to say about this company. Oppenheimer analysts stated on 26/04/2017 that they maintained their Underperform rating. Rafferty had a markedly different take on 26/04/2017, proposing that Capital One Financial Corporation is now considered Hold versus prior Buy rating. Instinet raised its rating on Capital One Financial Corporation to Buy on 29/03/2017 in a reversal from its prior Neutral rating. Goldman raised its rating on Capital One Financial Corporation to Buy on 17/02/2017 in a reversal from its prior Neutral rating.

Time To Rake In Healthy Returns From Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology, Inc.(PBYI) shares saw a recent bid of $79.75 and 2.12M shares have exchanged hands in the recent trading session, yielding a 110.98% gain over the past week. The stock price increased 2.18% or $-1.7 versus $78.05 at the end of the prior session. This change led market cap to move at $2.89B, putting the price -0.31% below the 52-week high and 188.58% above the 52-week low. The company’s stock has a normal trading capacity of 1.63M shares while the relative volume is 1.30.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $89.43 while $105.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $15.57 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $60.00, which would be decrease of about -25% of its current value. The mean target of $90.00 should be compared with the price when the stock was languishing around $27.64 a share. And it remains to be seen which target price PBYI can achieve without sacrificing much as the company is holding a 122.58% gain for the past twelve months.

By historical standards, Puma Biotechnology, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts  above the average P/E ratio of 137.90 times earnings. For now, Puma Biotechnology, Inc. is the toast of Wall Street as its ABR stands at 1.70 with 3 out of 7 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Puma Biotechnology, Inc. has a 26.16% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Puma Biotechnology, Inc. has far performed well this year, with the share price up 159.77% since January. Over the past 2 quarters, the stock is up 72.25%, compared with a gain of nearly 113.52% for 3 months and about 99.62% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $-1.97, smashing the consensus of $-1.98 per share. Revenue for the quarter also killed consensus, coming in at $0M, compared to the consensus of 0M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-2.03. The company is expected to report EPS as high as $-1.86 and as low as $-2.23 per share. Similarly, full-year EPS forecasts have ranged between $-10.71 and $-7.18. The mean EPS estimate is $-8.47. On the other side, sales forecasts for the current quarter are $0M. The stock is expected to report revenue as high as $0M and as low as $0M per share. Similarly, full-year sales forecasts have ranged between $7.29M and $50M. The mean revenue estimate is $22.97M.

Over the last 5 years, Puma Biotechnology, Inc. has averaged a -44.40% YoY EPS growth rate. Analysts are expecting EPS growth rates to be at -11.30% this quarter and EPS estimate for next year reflect a 51.40% growth rate.

Sell-side analysts also have something to say about this company. RBC Capital Mkts analysts stated on 25/05/2017 that they maintained their Sector Perform rating. RBC Capital Mkts analysts stated on 02/03/2017 that they maintained their Sector Perform rating. Credit Suisse analysts stated on 22/09/2016 that they maintained their Outperform rating. Stifel raised its rating on Puma Biotechnology, Inc. to Buy on 21/09/2016 in a reversal from its prior Hold rating.

DXC Technology Company (DXC) Share Price Could Be Rising After 32.38% gain In 2017

DXC Technology Company(DXC) shares saw a recent bid of $78.66 and 2.37M shares have exchanged hands in the recent trading session, yielding a 0.76% gain over the past week. The stock price increased 0.03% or $-0.02 versus $78.64 at the end of the prior session. This change led market cap to move at $22.26B, putting the price -2.68% below the 52-week high and 73.37% above the 52-week low. The company’s stock has a normal trading capacity of 2.92M shares while the relative volume is 0.81.

By historical standards, DXC Technology Company remains a cheap stock. The company’s current price-earnings ratio amounts  above the average P/E ratio of 20.25 times earnings. For now, DXC Technology Company is the toast of Wall Street as its ABR stands at 2.40 with 2 out of 17 analysts rating the stock a buy. Over the short term, some market observers may have noticed that DXC Technology Company has a 2.29% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. DXC Technology Company has far performed well this year, with the share price up 32.38% since January. Over the past 2 quarters, the stock is up 27.57%, compared with a gain of nearly 14.73% for 3 months and about 3.66% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $1.15, smashing the consensus of $0.83 per share. Revenue for the quarter also did not kill consensus, coming in at $1.89B, compared to the consensus of 1.94B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.47. The company is expected to report EPS as high as $1.68 and as low as $0.66 per share. Similarly, full-year EPS forecasts have ranged between $2.74 and $3.08. The mean EPS estimate is $2.80. On the other side, sales forecasts for the current quarter are $6.02B. The stock is expected to report revenue as high as $6.14B and as low as $5.9B per share. Similarly, full-year sales forecasts have ranged between $7.63B and $7.7B. The mean revenue estimate is $7.66B.

Over the last 5 years, DXC Technology Company has averaged a 50.10% YoY EPS growth rate and a -12.10% revenue growth rate. Analysts are expecting EPS growth rates to be at -306.40% this quarter and EPS estimate for next year reflect a 25.35% growth rate.

Sell-side analysts also have something to say about this company. Barclays analysts stated on 25/05/2017 that they launched coverage on this stock with Overweight rating. JP Morgan analysts stated on 19/04/2017 that they launched coverage on this stock with Overweight rating.

Dollar Tree, Inc. (DLTR) Traders Should Start Listening to Analysts

Dollar Tree, Inc.(DLTR) shares saw a recent bid of $78.28 and 2.18M shares have exchanged hands in the recent trading session, yielding a -1.76% decline over the past week. The stock price decreased -0.66% or $0.52 versus $78.80 at the end of the prior session. This change led market cap to move at $18.64B, putting the price -21.67% below the 52-week high and 7.90% above the 52-week low. The company’s stock has a normal trading capacity of 2.82M shares while the relative volume is 0.77.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $88.87 while $101.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $12.13 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $65.00, which would be decrease of about -17% of its current value. The mean target of $92.00 should be compared with the price when the stock was languishing around $72.55 a share. And it remains to be seen which target price DLTR can achieve without sacrificing much as the company is holding a -11.42% fall for the past twelve months.

By historical standards, Dollar Tree, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts to 21.47 times earnings, below the average P/E ratio of 24.98 times earnings. For now, Dollar Tree, Inc. is the toast of Wall Street as its ABR stands at 2.40 with 7 out of 27 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Dollar Tree, Inc. has a 2.59% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Dollar Tree, Inc. has far performed well this year, with the share price up 1.43% since January. Over the past 2 quarters, the stock is down -11.91%, compared with a fall of nearly -1.61% for 3 months and about -5.83% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $0.98, smashing the consensus of $0.98 per share. Revenue for the quarter also killed consensus, coming in at $5.29B, compared to the consensus of 5.29B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $0.87. The company is expected to report EPS as high as $0.93 and as low as $0.72 per share. Similarly, full-year EPS forecasts have ranged between $3.69 and $4.50. The mean EPS estimate is $3.85. On the other side, sales forecasts for the current quarter are $5.23B. The stock is expected to report revenue as high as $5.28B and as low as $5.19B per share. Similarly, full-year sales forecasts have ranged between $20.63B and $20.77B. The mean revenue estimate is $20.7B.

Over the last 5 years, Dollar Tree, Inc. has averaged a 13.40% YoY EPS growth rate and a 25.60% revenue growth rate. Analysts are expecting EPS growth rates to be at 199.50% this quarter and EPS estimate for next year reflect a 12.21% growth rate.

Sell-side analysts also have something to say about this company. Gordon Haskett analysts stated on 09/05/2017 that they launched coverage on this stock with Buy rating. Johnson Rice raised its rating on Dollar Tree, Inc. to Buy on 24/04/2017 in a reversal from its prior Accumulate rating. Atlantic Equities raised its rating on Dollar Tree, Inc. to Neutral on 04/04/2017 in a reversal from its prior Underweight rating. Credit Suisse raised its rating on Dollar Tree, Inc. to Neutral on 23/03/2017 in a reversal from its prior Underperform rating.

Will Wal-Mart Stores, Inc. (WMT) Surpass The Expectations That Analysts Have Set?

Wal-Mart Stores, Inc.(WMT) shares saw a recent bid of $78.13 and 6.11M shares have exchanged hands in the recent trading session, yielding a -0.81% decline over the past week. The stock price decreased -0.23% or $0.18 versus $78.31 at the end of the prior session. This change led market cap to move at $237.40B, putting the price -1.65% below the 52-week high and 19.68% above the 52-week low. The company’s stock has a normal trading capacity of 8.04M shares while the relative volume is 0.76.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $80.84 while $92.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $11.16 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $61.00, which would be decrease of about -22% of its current value. The mean target of $80.15 should be compared with the price when the stock was languishing around $65.28 a share. And it remains to be seen which target price WMT can achieve without sacrificing much as the company is holding a 10.28% gain for the past twelve months.

By historical standards, Wal-Mart Stores, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts to 17.73 times earnings, below the average P/E ratio of 41.91 times earnings. For now, Wal-Mart Stores, Inc. is the toast of Wall Street as its ABR stands at 2.60 with 5 out of 33 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Wal-Mart Stores, Inc. has a 2.56% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Wal-Mart Stores, Inc. has far performed well this year, with the share price up 13.04% since January. Over the past 2 quarters, the stock is up 10.31%, compared with a gain of nearly 8.91% for 3 months and about 3.57% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $1.00, smashing the consensus of $0.96 per share. Revenue for the quarter also did not kill consensus, coming in at $117.54B, compared to the consensus of 117.74B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.07. The company is expected to report EPS as high as $1.12 and as low as $1.02 per share. Similarly, full-year EPS forecasts have ranged between $4.27 and $4.57. The mean EPS estimate is $4.32. On the other side, sales forecasts for the current quarter are $122.86B. The stock is expected to report revenue as high as $124.43B and as low as $121.66B per share. Similarly, full-year sales forecasts have ranged between $483.57B and $488.19B. The mean revenue estimate is $485.86B.

Over the last 5 years, Wal-Mart Stores, Inc. has averaged a -0.60% YoY EPS growth rate and a 1.70% revenue growth rate. Analysts are expecting EPS growth rates to be at -4.00% this quarter and EPS estimate for next year reflect a 5.53% growth rate.

Sell-side analysts also have something to say about this company. Telsey Advisory Group analysts stated on 19/05/2017 that they maintained their Outperform rating. Gordon Haskett analysts stated on 09/05/2017 that they launched coverage on this stock with Buy rating. Telsey Advisory Group raised its rating on Wal-Mart Stores, Inc. to Outperform on 07/04/2017 in a reversal from its prior Market Perform rating. BofA/Merrill raised its rating on Wal-Mart Stores, Inc. to Buy on 22/02/2017 in a reversal from its prior Neutral rating.

Eli Lilly and Company (LLY) Trend of Beating EPS and Revenue Estimates

Eli Lilly and Company(LLY) shares saw a recent bid of $78.05 and 2.24M shares have exchanged hands in the recent trading session, yielding a 0.32% gain over the past week. The stock price decreased -0.37% or $0.29 versus $78.34 at the end of the prior session. This change led market cap to move at $86.44B, putting the price -10.00% below the 52-week high and 21.61% above the 52-week low. The company’s stock has a normal trading capacity of 3.93M shares while the relative volume is 0.57.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $89.09 while $102.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $12.91 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $69.00, which would be decrease of about -12% of its current value. The mean target of $90.00 should be compared with the price when the stock was languishing around $64.18 a share. And it remains to be seen which target price LLY can achieve without sacrificing much as the company is holding a 3.35% gain for the past twelve months.

By historical standards, Eli Lilly and Company remains a cheap stock. The company’s current price-earnings ratio amounts to 37.90 times earnings, above the average P/E ratio of 14.27 times earnings. For now, Eli Lilly and Company is the toast of Wall Street as its ABR stands at 2.10 with 7 out of 22 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Eli Lilly and Company has a 0.91% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Eli Lilly and Company has far performed well this year, with the share price up 6.12% since January. Over the past 2 quarters, the stock is up 14.78%, compared with a fall of nearly -6.03% for 3 months and about -4.03% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $0.98, smashing the consensus of $0.96 per share. Revenue for the quarter also killed consensus, coming in at $5.23B, compared to the consensus of 5.22B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.05. The company is expected to report EPS as high as $1.15 and as low as $0.98 per share. Similarly, full-year EPS forecasts have ranged between $4.07 and $4.19. The mean EPS estimate is $4.12. On the other side, sales forecasts for the current quarter are $5.61B. The stock is expected to report revenue as high as $5.7B and as low as $5.5B per share. Similarly, full-year sales forecasts have ranged between $21.89B and $22.33B. The mean revenue estimate is $22.08B.

Over the last 5 years, Eli Lilly and Company has averaged a -8.00% YoY EPS growth rate and a -2.70% revenue growth rate. Analysts are expecting EPS growth rates to be at 14.10% this quarter and EPS estimate for next year reflect a 5.87% growth rate.

Sell-side analysts also have something to say about this company. Argus had a markedly different take on 27/04/2017, proposing that Eli Lilly and Company is now considered Hold versus prior Buy rating. Morgan Stanley had a markedly different take on 17/04/2017, proposing that Eli Lilly and Company is now considered Equal-Weight versus prior Overweight rating. Barclays analysts stated on 07/04/2017 that they maintained their Overweight rating. UBS analysts stated on 20/03/2017 that they maintained their Neutral rating.

Qorvo, Inc. (QRVO): Start Paying Attention to Revised Ratings

Qorvo, Inc.(QRVO) shares saw a recent bid of $77.84 and 1.35M shares have exchanged hands in the recent trading session, yielding a 3.09% gain over the past week. The stock price decreased -1.26% or $0.99 versus $78.83 at the end of the prior session. This change led market cap to move at $10.02B, putting the price -1.87% below the 52-week high and 61.23% above the 52-week low. The company’s stock has a normal trading capacity of 1.65M shares while the relative volume is 0.82.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $76.64 while $95.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $18.36 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $57.00, which would be decrease of about -27% of its current value. The mean target of $76.50 should be compared with the price when the stock was languishing around $48.28 a share. And it remains to be seen which target price QRVO can achieve without sacrificing much as the company is holding a 54.05% gain for the past twelve months.

By historical standards, Qorvo, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts  above the average P/E ratio of 23.33 times earnings. For now, Qorvo, Inc. is the toast of Wall Street as its ABR stands at 2.60 with 4 out of 25 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Qorvo, Inc. has a 8.70% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Qorvo, Inc. has far performed well this year, with the share price up 47.62% since January. Over the past 2 quarters, the stock is up 42.54%, compared with a gain of nearly 15.11% for 3 months and about 9.45% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $0.85, smashing the consensus of $0.81 per share. Revenue for the quarter also killed consensus, coming in at $642.99M, compared to the consensus of 631.93M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.52. The company is expected to report EPS as high as $1.61 and as low as $1.40 per share. Similarly, full-year EPS forecasts have ranged between $4.34 and $4.60. The mean EPS estimate is $4.52. On the other side, sales forecasts for the current quarter are $839.64M. The stock is expected to report revenue as high as $879.7M and as low as $726.4M per share. Similarly, full-year sales forecasts have ranged between $3.02B and $3.04B. The mean revenue estimate is $3.02B.

Over the last 5 years, Qorvo, Inc. has averaged a -66.30% YoY EPS growth rate and a 28.30% revenue growth rate. Analysts are expecting EPS growth rates to be at 35.90% this quarter and EPS estimate for next year reflect a 16.99% growth rate.

Sell-side analysts also have something to say about this company. Needham analysts stated on 26/05/2017 that they maintained their Buy rating. Cowen analysts stated on 26/05/2017 that they maintained their Market Perform rating. Drexel Hamilton analysts stated on 25/05/2017 that they maintained their Buy rating. Craig Hallum analysts stated on 04/05/2017 that they maintained their Buy rating.

The Sell-Side Reaction To American Express Company (AXP)’s Recent Shift

American Express Company(AXP) shares saw a recent bid of $77.46 and 1.85M shares have exchanged hands in the recent trading session, yielding a 0.86% gain over the past week. The stock price increased 0.03% or $-0.02 versus $77.44 at the end of the prior session. This change led market cap to move at $69.21B, putting the price -5.54% below the 52-week high and 35.54% above the 52-week low. The company’s stock has a normal trading capacity of 3.85M shares while the relative volume is 0.48.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $83.74 while $95.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $11.26 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $63.00, which would be decrease of about -19% of its current value. The mean target of $85.00 should be compared with the price when the stock was languishing around $57.15 a share. And it remains to be seen which target price AXP can achieve without sacrificing much as the company is holding a 18.75% gain for the past twelve months.

By historical standards, American Express Company remains a cheap stock. The company’s current price-earnings ratio amounts to 14.03 times earnings, below the average P/E ratio of 38.93 times earnings. For now, American Express Company is the toast of Wall Street as its ABR stands at 2.50 with 8 out of 32 analysts rating the stock a buy. Over the short term, some market observers may have noticed that American Express Company has a 1.57% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. American Express Company has far performed well this year, with the share price up 4.56% since January. Over the past 2 quarters, the stock is up 6.28%, compared with a fall of nearly -3.38% for 3 months and about -3.57% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $1.34, smashing the consensus of $1.28 per share. Revenue for the quarter also killed consensus, coming in at $7.89B, compared to the consensus of 7.75B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $1.43. The company is expected to report EPS as high as $1.61 and as low as $1.34 per share. Similarly, full-year EPS forecasts have ranged between $5.37 and $5.82. The mean EPS estimate is $5.71. On the other side, sales forecasts for the current quarter are $8.18B. The stock is expected to report revenue as high as $8.39B and as low as $7.98B per share. Similarly, full-year sales forecasts have ranged between $31.49B and $33.55B. The mean revenue estimate is $32.74B.

Over the last 5 years, American Express Company has averaged a 6.70% YoY EPS growth rate and a 0.30% revenue growth rate. Analysts are expecting EPS growth rates to be at 12.00% this quarter and EPS estimate for next year reflect a 10.89% growth rate.

Sell-side analysts also have something to say about this company. Instinet raised its rating on American Express Company to Neutral on 27/04/2017 in a reversal from its prior Reduce rating. Guggenheim raised its rating on American Express Company to Buy on 25/04/2017 in a reversal from its prior Neutral rating. Keefe Bruyette raised its rating on American Express Company to Outperform on 30/01/2017 in a reversal from its prior Mkt Perform rating. JP Morgan raised its rating on American Express Company to Overweight on 17/01/2017 in a reversal from its prior Neutral rating.